NeuroThera Labs Inc. has seen significant price volatility this week, closing down nearly 48%.
NeuroThera Labs Inc. (NTLX.V) has experienced a sharp decline in its stock price, dropping 47.73% over the past week. This dramatic move comes amid industry news related to the company's subsidiary, CliniQuantum.
Advertisement
NeuroThera Labs Inc.
NTLX.V
NTLX.V
NeuroThera Labs Inc.
WealthAwesomeMarket cap
$373.56M
52W high
$5.32
52W low
$2.10
1W change
-47.73%
Beta
-0.02
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NTLX's historical volatility
30-Day Vol
256.9%
Annualized
90-Day Vol
194.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.92
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.17 | C$0.89 – C$5.26 |
| 60 trading days | C$2.04 | C$0.58 – C$7.15 |
| 90 trading days | C$1.92 | C$0.41 – C$8.93 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of the recent technological advancements reported by CliniQuantum and how they might influence NeuroThera Labs' future performance, especially in light of the current stock price volatility.
Stock Plummets Nearly 48% This Week
NeuroThera Labs closed at C$2.30, significantly lower than its 50-day moving average of C$4.23.
Bull case
CliniQuantum's recent successful analysis could lead to innovative solutions in gene therapy. This progress might improve NeuroThera Labs' market position and attract more investor interest.
Bear case
The steep price drop raises concerns about the company's financial health and operational viability, especially considering its negative profit margins and return on equity.
Price Action Overview
Advertisement
NeuroThera Labs Inc. has seen a staggering 47.73% decline in its stock price this week, closing at C$2.30. Over the past month, the stock has decreased by 31.55%, reflecting ongoing challenges in the market. Year-to-date, the stock is down 3.36%, indicating a lack of upward momentum.
Recent Company News
On October 7, SciSparc announced that its subsidiary, NeuroThera Labs, successfully conducted a quantum-enabled analysis of billions of gene combinations using real-world clinical data. This development could have significant implications for the company's future, particularly in the realm of gene therapy and personalized medicine.
Technical Picture
From a technical standpoint, NeuroThera Labs' stock is performing well below its moving averages. The current price of C$2.30 is 45.6% lower than the 50-day moving average of C$4.23 and 23.3% below the 200-day moving average of C$3.00. The stock has traded within a 52-week range of C$2.10 to C$5.32, with the current price sitting at only 6% of that range. The stock's beta is -0.02, indicating a low correlation with market movements, while the current trading volume of 100 shares is only 0.02 times the 20-day average volume of 5,023 shares.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
